Does the LOY-001 Dog Longevity Drug Really Work?

By Jeanette Wilson, DVM, CVA, CVCH, CVTP, CVFT, CTCVMP, CTPET

✓ Medically reviewed by Jeanette Wilson, DVM, CVA, CVCH, CVTP, CVFT, CTCVMP, CTPET — August 31, 2026 For general education — not a substitute for veterinary care.

Longevity · August 29, 2026 · 5 min read

LOY-001 hasn't been proven to add healthy years yet — here's what the FDA's milestone does and doesn't tell you.

A ten-year-old mastiff mix named nothing you’d recognize came into a colleague’s exam room this spring, and her owner had already read three headlines about a “longevity drug for dogs.” She wanted to know if she should wait for it instead of starting anything else at 132 pounds and ten years old. That question is more common now than it was even a year ago, and it deserves a straight answer instead of hype.

What LOY-001 actually is

LOY-001 is an investigational injectable developed by the biotech company Loyal, aimed at large- and giant-breed dogs age seven and up who weigh at least 40 pounds. It’s given by a veterinarian roughly every three to six months, not as a daily chew or pill. The mechanism is specific: it’s designed to lower insulin-like growth factor 1 (IGF-1), a hormone tied to growth and, in several species, to lifespan — big dogs run higher IGF-1 than small dogs, and that gap tracks with big dogs’ shorter average lifespans. In late 2023, Loyal announced that the FDA Center for Veterinary Medicine agreed its data supports a “reasonable expectation of effectiveness” for large-dog lifespan extension — reportedly the first time the agency has made that determination for any lifespan-extension drug in any species.

What “reasonable expectation of effectiveness” does not mean

This is the part owners skip past, and it’s the part I sit with the longest. A reasonable-expectation finding is a regulatory pathway checkpoint, not proof the drug extends healthy years in the real world. Loyal still has to complete manufacturing and safety work, and — as dvm360 reported, the company has discussed a large trial involving roughly 1,000 large and giant dogs, targeting at least a year of added lifespan as the goal, not a confirmed result. Nothing about that trajectory tells you what happens in your own 40-, 80-, or 130-pound dog between now and whenever LOY-001 reaches full approval and a pharmacy shelf. I don’t treat a regulatory milestone as a clinical outcome, and neither should you.

Where the four modalities come in while you wait

I don’t tell owners to sit on their hands until a single injectable clears the finish line. My approach braids four things into one whole-patient plan — nutrition, movement and bodywork, targeted supplementation, and, where it fits the pattern, acupuncture or herbal support — because aging in a large-breed dog is rarely one pathway going wrong. IGF-1 signaling matters, but so does joint load, muscle mass, oxidative stress, and the day-to-day stuff LOY-001 was never built to touch, like mobility and appetite. A drug aimed narrowly at one hormone axis, even a promising one, is not a substitute for that whole-patient plan; it’s one more input into it, once it’s actually available and your vet has weighed in.

A patient who complicated the wait-and-see plan

I had a case that pushed back on tidy advice. A nine-year-old Bernese mountain dog, 95 pounds, came in with her owner asking to “just wait for the injectable” rather than start anything else. By week six, her gait had visibly stiffened on stairs, and her owner was the one who noticed it first. Waiting for a drug still years from full approval meant losing ground on joint support and conditioning she could have started that day. That’s the tradeoff nobody puts in the headline: a promising pipeline drug can’t retroactively cover the months a dog spends without any plan at all.

What the ingredient evidence can and can’t tell you today

Because LOY-001 isn’t available yet, most owners asking this question are really asking what they can do now. Several ingredients marketed for canine longevity have real, if early, research behind them. Nicotinamide riboside is a NAD+ precursor studied for supporting normal cellular function. Quercetin is a flavonoid with antioxidant properties studied for immune and cellular support — though it’s worth being precise about what that evidence covers: in one study looking at quercetin, unformulated Q, NAC, and ascorbic acid, the tested concentrations “did not affect the feeding behavior of the worms,” per research published in Pharmaceuticals — a reminder that antioxidant research often starts in simple model organisms, not dogs, and shouldn’t be read as a lifespan guarantee. Resveratrol shows a similar pattern: in one in-vitro study, embryonic exposure to a 50 μg/ml dose “accelerated pupation and adult emergence but shortened adult lifespan,” according to research in Phytomedicine — evidence that dose and life stage change outcomes even in the same compound, which is exactly why I don’t extrapolate insect or cell-culture data onto a dog’s dinner bowl without a lot of caution.

An edge case that changes the calculus

Not every dog is a candidate for “wait and see,” and not every large dog fits LOY-001’s eventual profile even once it’s approved. A twelve-year-old Great Dane at 140 pounds with early kidney values already trending the wrong way is not a dog where I’d bank a plan on a not-yet-approved injectable timed for dogs newly entering their senior years. By day 10 of adjusting her diet and adding gentle Tui-na bodywork for comfort, her owner reported she was moving to greet visitors again, something she hadn’t done in weeks. That’s not proof of anything at a population level — it’s one dog, one plan — but it’s the kind of case that keeps me from treating any single drug, however well-designed, as the whole answer for an aging large-breed dog.

Comparing the actual choices in front of you

If you’re deciding what to do with a senior large-breed dog this year, the honest options are: talk to your vet about a comprehensive plan now, evaluate supplement ingredients on their actual evidence rather than marketing copy, and treat LOY-001 as a “watch this space” development rather than a current option. For readers comparing specific longevity chews on the market, our breakdowns on chew versus powder absorption, how Denamarin/SAM-e compares with longevity chews for liver support, and whether human quercetin capsules are a reasonable substitute walk through the label-reading questions worth asking before you buy anything.

The verdict

LOY-001 has cleared a genuinely notable regulatory bar, but “reasonable expectation of effectiveness” is not the same as a proven result in your dog, and it isn’t on the market yet. I don’t think any owner should delay a whole-patient plan — nutrition, movement, targeted supplementation, and bodywork or acupuncture where it fits — waiting for one injectable to finish its trial. Individual dogs vary widely, and your own veterinarian is the one who can weigh LOY-001, once available, against everything else already on your dog’s plan.